We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Technology Could Help Diagnose Sepsis in Hours

By LabMedica International staff writers
Posted on 08 Nov 2016
Image: A new microfluidics chip being developed for a blood test to rapidly diagnose sepsis would enable doctors to intervene sooner and as necessary, as well as to monitor treatment progress (Photo courtesy of Pappas Lab / Texas Tech University).
Image: A new microfluidics chip being developed for a blood test to rapidly diagnose sepsis would enable doctors to intervene sooner and as necessary, as well as to monitor treatment progress (Photo courtesy of Pappas Lab / Texas Tech University).
Researchers have developed a microfluidics chip that detected mock-sepsis conditions within a few hours, instead of at least two days by currently used methods. As sepsis left untreated can be fatal in as little as two days, a rapid blood test would provide medical professionals with a critical window of time in which to begin early antibiotics treatment of diagnosed patients.

“Normally when you detect sepsis, you do it through bacterial culture; that takes two days on the short end to 15 days on the long end. Most people die of sepsis at two days. The detection currently is on the exact same time scale as mortality, so we’re trying to speed that up,” said Dimitri Pappas, associate professor of chemistry at Texas Tech University (Lubbock, TX, USA), “Instead of the bacteria, we’re looking at the body’s immune response to those bacteria, because that’s what you really care about: the bacteria cause the infection, but it’s the body’s response that causes sepsis.” It begins with a systemic inflammatory response then progresses into sepsis and eventually septic shock, in which blood pressure plummets and organs fail.

“In the elderly, in people who are immune-compromised – people who have had surgeries, for example, or burns or they’re already fighting off infection – and in children as well, you see a runaway immune response where the body’s act of saving itself can actually be lethal,” said Prof. Pappas. When not fatal, sepsis can result in amputation of a limb or prolonged hospitalization.

Sepsis is suspected by a patient’s abnormal body temperature and rapid heart and breathing rates. “Those are all incredibly crude measurements,” said Prof. Pappas, “It leads to a lot of false positives.” Because doctors know the bacterial culture likely will take longer than a septic patient’s life span, they often order treatment immediately. “The way they treat sepsis right now is through a massive antibiotic administration,” said Prof. Pappas “That’s good, actually, but if you do it prophylactically and when it’s not needed, you’re basically helping create drug-resistant bacteria. So there’s a need to detect sepsis and to treat it but not to over treat it.”

To successfully treat septic patients, doctors need two critical pieces of information: the microorganism causing the infection and whether it can be eradicated by antibiotics. “Waiting for that information over several days is one of the main problems and reasons for the devastating outcomes,” said Dr. John Griswold, professor and chair emeritus, Department of Surgery, TTU’s Health Sciences Center, “Dr. Pappas has developed a test that should give us at least the indication of bacterial invasion within a matter of hours as opposed to days. The sooner we have an indication of microorganism invasion, the sooner we are on the path to successful treatment of these very sick patients.” Prof. Griswold added that sepsis is considered one of the most costly diseases in healthcare.

Prof. Pappas and graduate student Ye Zhang recently filed a provisional patent for a microfluidics chip that can speed up detection. “We can take a blood sample, introduce it into this chip and capture one cell type or move fluids around and add chemicals to dye the cells certain colors and do diagnostic measurements,” said Prof. Pappas.

Using their chip, a sepsis diagnosis can be confirmed in just four hours. “That rapid detection will let doctors intervene sooner and intervene when necessary, but it also allows them not just to detect it but to follow up treatment,” said Prof. Pappas, “you can follow and retest them over time to make sure the body’s response is returning to normal.”

Another advantage is that the chip requires less than a drop of blood per test. “It’s so minimal we could do this multiple times throughout the course of the treatment of the patient. If they’re not septic at hour zero, but they still look septic by other methods, we could test them in six hours and see if they’ve progressed or not,” said Prof. Pappas.

The chips are designed to detect certain white blood cells activated by the immune system to fight the infection. To this point, all testing has been done with using transformed stem cells. “We have stem cells that we transform into white blood cells, then we trick them into thinking there’s an infection. We add those infection-response blood cells to human blood in the concentrations we want and the timeframe we want,” said Prof. Pappas. The blood is then tested to see if the chip registers it as septic. “That allows us to refine the technique to make sure it’ll work, because human samples are far more variable,” he said, “Before moving to humans, we had to show it’ll work in the first place.”

“Ultimately, this type of work – for it to be successful – has to be commercialized,” he said. “It has to be out there in the hands of physicians.” The next step is to test the chip with patient blood. In collaboration with Dr. Griswold, Dr. Pappas will now begin enrolling patients.

Related Links:
Texas Tech University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Portable POCT Blood Gas Analyzer
BD100
Thyroid Test
Anti-Thyroid EIA Test

Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more